NAC Global Tech Inc. (fka NACG)

[NORTH LAND]

http://www.nacglobaltechnologies.com/PDF/NAC Fact Sheet.pd

[NORTH LAND]

NACG .035 was $1.60 150mAS hmmmmmmmm

[NORTH LAND]

NACG .035 Downtrend Broken

[jjr04001]

Don't know what this is, but chart says buy.

[mannken]

Business strategy and overview

Lengthy, but a must read for any long term investor, starting on page 5

http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=10103839

[mannken]

And another


NAC Global Technologies Announces Successful Test of New Turbine Technology

Marketwired NAC Global Technologies
September 16, 2014 8:58 AM

JACKSONVILLE, FL--(Marketwired - Sep 16, 2014) - NAC Global Technologies (OTCBB: NACG) today announced the successful first stage testing of its HGT Turbine Drive, a harmonic gearing transmission technology for fluid and wind turbine energy production.

Mr. Vincent Genovese, Chairman and CEO of NAC, said, "We are very pleased to announce another milestone in NAC's development of new technologies for clean, renewable energy. We initiated testing in 2012, and we are confident in both our technology and ability to produce robust drives for energy generation. NAC is now embarking on the development of unique, application specific designs of renewable energy drives for residential and commercial energy generation. Our designs are intended to efficiently convert existing available energy into electrical energy in both intermittent and continual use applications.

We understand the need for aesthetics, and believe that only with considering curb-side appeal can clean energy technologies make broad inroads into residential and commercial construction. We believe our products will meet that need and can integrate seamlessly into the standard construction of nearly every occupied building. NAC is eager to move this initiative forward, and we expect the first units to be released for manufacturing within the coming year," concluded Mr. Genovese.

About NAC Global Technologies
NAC Global Technologies is a development and manufacturing company operating in the automation, energy, defense, robotics, and medical industries. The company focuses on supplying critical technologies to meet key national and global needs in existing and emerging multi-billion dollar markets. The company's first product offering is harmonic gearing technology (HGT), in which the company's management has decades of experience. Expanding from this market entrance point, the company is building a portfolio of synergistic technologies and has strategic initiatives in place to expand its market and application reach into emerging clean energy and force sensing robotics for industrial and medical applications.

The Company has its corporate headquarters in Jacksonville, FL, and has one operating subsidiary, NAC Drive Systems Inc. NAC manufactures and warehouses products in Port Jervis, NY and in Beijing, China via a strategic partnership agreement with CTKM Beijing Harmonic Drive, Ltd., the national HGT supplier to the China Space Agency. More Information is available at: www.nacdrivesystems.com

Forward-looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which contain words such as "expect," "believe" or "plan," by their nature address matters that are, to different degrees, uncertain. These uncertainties may cause actual future events to be materially different than those expressed in our forward-looking statements. We do not undertake to update our forward-looking statements.
Contact:
Investor
Kirin M. Smith
Chief Operating Officer
ProActive Capital Group
D: 646.863.6519
641 Lexington Avenue, 6th Floor
New York, NY 10022
www.proactivecapital.com

[mannken]

How about this news today after the LipidViro reverse merger

This company should be a great investment for anyone with the right time horizon IMO


NAC Global Technologies Awarded Ten Year Supply Agreement

Marketwired NAC Global Technologies
3 hours ago

JACKSONVILLE, FL--(Marketwired - Sep 18, 2014) - NAC Global Technologies (OTCQB: NACG) today announced it has been awarded a ten year supply agreement for harmonic gearing with Legacy Press Company, a flexographic printing press manufacturer of Fort Mill, SC. The Company's HGT drives are applied on Legacy's line of narrow web label presses, providing 360 degree dynamic phase adjustment of the print, die and sheet register.

Mr. Vincent Genovese, Chairman and CEO of NAC, said, "This long term supply agreement clearly highlights solid traction as we continue to implement our growth strategy. NAC has worked very closely with Legacy and is pleased to enter into this long term supply agreement. Our drive performance and business philosophy of working as a vendor-partner resulted in this agreement and represents strong validation. We truly strive to help our customers achieve their business goals, and I believe this agreement is of mutual benefit to both companies. We look forward to working with Legacy in the coming years."

About NAC Global Technologies
NAC Global Technologies is a development and manufacturing company operating in the automation, energy, defense, robotics, and medical industries. The company focuses on supplying critical technologies to meet key national and global needs in existing and emerging multi-billion dollar markets. The company's first product offering is harmonic gearing technology (HGT), in which the company's management has decades of experience. Expanding from this market entrance point, the company is building a portfolio of synergistic technologies and has strategic initiatives in place to expand its market and application reach into emerging clean energy and force sensing robotics for industrial and medical applications.

The Company has its corporate headquarters in Jacksonville, FL, and has one operating subsidiary, NAC Drive Systems Inc. NAC manufactures and warehouses products in Port Jervis, NY and in Beijing, China via a strategic partnership agreement with CTKM Beijing Harmonic Drive, Ltd., the national HGT supplier to the China Space Agency. More Information is available at: www.nacglobaltechnologies.com

Forward-looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which contain words such as "expect," "believe" or "plan," by their nature address matters that are, to different degrees, uncertain. These uncertainties may cause actual future events to be materially different than those expressed in our forward-looking statements. We do not undertake to update our forward-looking statements.
Contact:
Investor
PCG Advisory Group, LLC
Scott Powell
Managing Director
Tel: [phone]
Email: Email Contact
www.pcgadvisory.com

[Renee]

LipidViro Tech Inc., LPVO changed to NAC Global Tech Inc., NACG:

http://www.otcbb.com/asp/dailylist_detail.asp?d=07/17/2014&mkt_ctg=OTCBB

[DeafTrader2]

LPVO NEWS OUT ! KABOOOM TOMORROW MORNING... CHANGE OF CONTROLS AND DIRECTORS >>> .....

[winstoncooper]

Wow.....You were right! It took 6 long years...but you were right!!

[Nomad505]

Looks like today is your chance to sell then. Up over 100%.

[53chevy]

Looks like you've got yourself an RM play.......good luck!

http://www.sec.gov/Archives/edgar/data/6732/000101041208000025/form8k12808.htm

[frankie_fillet]

these all have short shelf lives or they meld into other companies.

real

[hawkeyes8]

Can't beleive I got suckered into this stock... What a LOSER Company.
going out of business....

[hawkeyes8]

Go to there website and read there latest release. don't fully understand it , but it doesn't sound like good news...

[john wayne]

Thanks for the info. I was watching to see if it dropped below .02, but it looks like it may have bottomed yesterday morning. I don't usually play stocks over .02.

Good luck to you.

[hawkeyes8]

John:
Being invested in some other stocks as well , I know that when I don't see anything transpiring with a company , people assume there is nothing going on and sell.
Lipid-Viro has not updated there website for well over a year and this may scare some investors.
I have sent a few e-mails to them and I believe they are in the 100 person trial stage with there product
I e-mailed them yesterday and inquired to where they are at in there timeline but have not heard back yet.
I have been a investor since 2002 , and believe they have the potential to make some serious money in the future , but without info. coming out at some point , it's scary. I have been informed that they are working on updating there website but that was about 4-5 months ago. Let you know more as I get it. You can e-mail them ( off there website ) and ask for there " executive summary ". gives a breakdown as to there milestones and timelines...

[john wayne]

Any idea why this is tanking so bad?
Are you from Iowa? I am from Des Moines

[hawkeyes8]

CEO of Lipidviro
I have been an investor in this Co. four years, (Possibly to long) Can you give me some updates ? ? ? nothing on the website since 4-18-06

[frankie_fillet]

Proprietary Anti-Inflammatory Treatment for Acute Ischemic Stroke and Chronic Heart Failure
LipidViro Tech, Inc. (OTCBB: LPVT), a medical device company developing a new device-based, multi-therapeutic platform -- d-OSAB -- targeting acute ischemic stroke and chronic heart failure, announced that J. S. Latino, co-founder and Head of Research, and Linda Sharkus, Ph.D., Director, will attend Medtech Insight's "Investment In Innovation Medical Device Summit: A Preview of Early-Stage Medical Technology Companies" being held June 3-5, 2007, at the Grand Hyatt Hotel in San Francisco.

Mr. Latino's presentation is scheduled for 2:30 p.m. PDT on Monday, June 4, and will include an overview of the Company's proprietary technology, competitive advantages, plan to commence a 100-patient Phase IIa ischemic stroke study, and commercialization strategy.

About LipidViro Tech, Inc.

LipidViro Tech is a development-stage medical device company engaged in research and commercial development of its device-based, multi-therapeutic platform -- d-OSAB -- to treat ischemic brain stroke and chronic heart failure, diseases with few viable treatment options at present and markets exceeding $20 billion annually in the U.S. and EU. Stroke is the second leading cause of death worldwide, responsible for 4.4 million deaths each year. Annually, more than 1.5 million people in the U.S. and EU become victims of ischemic stroke. The single approved therapeutic for ischemic brain stroke patients is Tissue Plasminogen Activator (tPA), but patients are eligible for tPA only during a three-hour window from time of stroke; tPA use after three hours causes bleeding in the brain which may prove fatal. Consequently, only 6% of U.S. stroke patients and less than 1% of EU stroke patients utilize tPA. Anecdotal data suggests d-OSAB may be an effective stroke therapeutic for the majority of those untreated patients. During 2007, the Company is scheduled to commence a 100-patient Phase IIa study -- using d-OSAB to treat patients who have suffered an ischemic brain stroke -- to confirm these clinical findings.

Forward-looking Statements

This release contains forward-looking statements concerning plans, objectives, goals, strategies, future events or performance, which are not statements of historical fact. The forward-looking statements contained in this release reflect Management's current beliefs and expectations. Actual results or performance may differ materially from what is expressed in the forward-looking statements. Readers are referred to the documents filed by the Company with the SEC, specifically reports on Form 10-K and Form 10-Q including risk factors that could cause actual results to differ from forward-looking statements. These reports are available at www.sec.gov.

Contact:
Allen & Caron
Dan Matsui
949-474-4300

LipidViro Tech, Inc.
Linda Sharkus, PhD
732-280-8425
[e-mail]

[frankie_fillet]

LIPIDVIRO TECH INC: NT 10-Q,

[frankie_fillet]

in the process of getting stockcharts to cover this stock.